Full Text | PDF

Theranostics 2018; 8(3):812-814. doi:10.7150/thno.24183 This issue Cite

Editorial

“Albumin Hitchhiking” with an Evans Blue Analog for Cancer Theranostics

Emily B. Ehlerding¹, Xiaoli Lan^2✉, Weibo Cai^{1,3,4 ✉}

1. Department of Medical Physics, University of Wisconsin - Madison, Madison, WI 53705
2. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3. Department of Radiology, University of Wisconsin - Madison, Madison, WI 53705
4. Carbone Cancer Center, University of Wisconsin - Madison, Madison, WI 53705

✉ Corresponding author: Xiaoli Lan: Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Email: LXL730724com. Weibo Cai: 1111 Highland Ave, Madison, WI 53705, USA; Phone: 608-262-1749; Fax: 608-265-0614. Email: wcaiorg More

Abstract

Although ¹⁷⁷Lu-DOTA-TATE was recently approved in Europe for the treatment of certain neuroendocrine tumors, continued development and optimization has been ongoing to further improve the therapeutic efficacy of somatostatin receptor 2 targeted peptide receptor radionuclide therapy, as well as reducing the renal toxicity. In this work, the use of an Evans blue analog for “albumin hitchhiking” resulted in significant improvement in both the imaging performance and therapeutic efficacy of radiolabeled octreotate, as well as reducing the toxicity since much less radioactivity was used for therapy. Upon clinical translation, such “albumin hitchhiking” could make significant impact in the near future for cancer patient management.

Keywords: somatostatin receptor 2 (SSTR2), peptide receptor radionuclide therapy (PRRT), octreotate (TATE), positron emission tomography (PET), theranostics, cancer, precision medicine

Citation styles

©2024 Ivyspring International Publisher. Terms of use